<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990132</url>
  </required_header>
  <id_info>
    <org_study_id>RJ1 09/N070</org_study_id>
    <nct_id>NCT00990132</nct_id>
  </id_info>
  <brief_title>Home Mechanical Ventilation vs Home Oxygen Therapy in COPD</brief_title>
  <official_title>Randomised Controlled Trial of Home Mechanical Ventilation in Hypercapnic Chronic Obstructive Pulmonary Disease Patients Post Acute Hypercapnic Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patrick Murphy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guy's &amp; St Thomas' Charity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Respironics International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ResMed Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the effect of home mechanical ventilation (HMV) in&#xD;
      patients with severe chronic obstructive pulmonary disease (COPD). The purpose of the trial&#xD;
      is to test the hypothesis that HMV and longterm oxygen therapy (LTOT) increases admission&#xD;
      free survival compared with LTOT alone. More specifically, compared with LTOT, HMV and LTOT&#xD;
      reduces hospital re-admission in COPD patients who remain persistently hypercapnic following&#xD;
      an acute exacerbation requiring non-invasive ventilation (NIV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although HMV has been shown to improve physiological parameters as well as have clinical&#xD;
      benefits in terms of dyspnoea and exercise capacity in severe COPD, the published randomised&#xD;
      controlled trials have been less positive. The Steering Committee are committed to design a&#xD;
      robust clinical trial that will answer this clinical question. Therefore, a multi-centre&#xD;
      randomised controlled trial has been designed with recruitment and power calculations based&#xD;
      on the applicants own data.&#xD;
&#xD;
      We will recruit from 8 UK university centres with expertise in HMV, 116 hypercapnic patients&#xD;
      (58 in each arm) with persistent hypercapnia following an episode of acute hypercapnic&#xD;
      respiratory failure. During the acute hypercapnic episode the patient would have be eligible&#xD;
      for non-invasive ventilation with a pH &lt;7.35 and a partial pressure of carbon dioxide (PaCO2)&#xD;
      &gt; 7.0kPa. They will be randomised, for a 12 months, to either&#xD;
&#xD;
        1. HMV and LTOT (Treatment Group)&#xD;
&#xD;
        2. LTOT alone (Control Group) This study would allow the investigators to answer a number&#xD;
           of questions pertaining to clinical efficacy of HMV in COPD as well as the mechanism of&#xD;
           action of HMV in COPD&#xD;
&#xD;
             -  Does HMV effect admission-free survival?&#xD;
&#xD;
             -  Does HMV reduce exacerbation frequency?&#xD;
&#xD;
             -  Does HMV impact on disease progression?&#xD;
&#xD;
             -  Does HMV improve health-related quality of life?&#xD;
&#xD;
             -  Does HMV improve exercise capacity?&#xD;
&#xD;
             -  Is there a dose-response between hours of ventilator compliance and daytime PaO2&#xD;
                and PaCO2?&#xD;
&#xD;
             -  Do patients increase hours of ventilator use during acute exacerbations?&#xD;
&#xD;
             -  Is ventilator compliance with HMV and LTOT acceptable?&#xD;
&#xD;
             -  Does HMV reduce healthcare utilisation? Follow-up assessments will be performed at&#xD;
                6 weeks, 3, 6 and 12 months. These data collected will include admission-free&#xD;
                survival (primary outcome), hours of compliance with HMV, HRQL, gas exchange, lung&#xD;
                function, body composition, exercise capacity, exacerbation frequency primary care&#xD;
                consultations and compliance with LTOT, time to withdrawal of LTOT/night-time&#xD;
                oxygen therapy based on daytime PaO2 and overnight SaO2 (secondary outcome&#xD;
                measures). The relation of any changes to factors predicting severity of COPD will&#xD;
                be studied. The cost effectiveness and cost-utility analysis of HMV will be&#xD;
                studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days from trial intervention to either hospital admission or death</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry - specifically FEV1 &amp; FVC change from trial intervention to follow up.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Health related quality of life from pre-intervention to follow up - specifically outcomes of severe respiratory insufficiency questionnaire, chronic respiratory disease questionnaire &amp; MRC dyspnoea score</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial PaCO2 from pre-intervention to follow up</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the incremental shuttle walk test from pre-intervention to follow up</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of acute exacerbations of COPD requiring addition of antibiotics and or steroids and or hospital admission</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Long term oxygen therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LTOT will be established as per current national guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Home mechanical ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be set up on LTOT as per national guidelines and nocturnal non-invasive ventilation in accordance with study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Home mechanical ventilation</intervention_name>
    <description>Nocturnal non-invasive ventilation</description>
    <arm_group_label>Home mechanical ventilation</arm_group_label>
    <other_name>Harmony 2</other_name>
    <other_name>VPAP III STA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Long term oxygen therapy</intervention_name>
    <description>LTOT established as per national guidelines</description>
    <arm_group_label>Long term oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with COPD&#xD;
&#xD;
          -  Acute hypercapnic exacerbation of COPD at least 2 weeks previously&#xD;
&#xD;
          -  Tolerated non-invasive ventilation during acute hypercapnic exacerbation&#xD;
&#xD;
          -  Chronic hypoxia requiring LTOT (PaO2 &lt;7.3kPa or a PaO2 &gt;7.3 and &lt;8.0kPa and one of the&#xD;
             following: secondary polycythaemia; nocturnal hypoxaemia SaO2 &lt;90% for &gt;30% of the&#xD;
             time; peripheral oedema; or PHT)&#xD;
&#xD;
          -  Chronic hypercapnia (PaCO2 &gt;7kPa)&#xD;
&#xD;
          -  â‰¥20 pack year smoking history&#xD;
&#xD;
          -  FEV1/FVC &lt;60%&#xD;
&#xD;
          -  FEV1 at &lt;50% predicted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persistent hypercapnic respiratory failure with acidosis (defined as pH &lt;7.30 after&#xD;
             bronchodilators)&#xD;
&#xD;
          -  Development of worsening hypercapnic respiratory failure with acidosis during&#xD;
             initiation of LTOT therapy&#xD;
&#xD;
          -  Failure to tolerate NIV during the acute illness preceding trial identification&#xD;
&#xD;
          -  Post extubation or decannulation following AHRF requiring intubation&#xD;
&#xD;
          -  Restrictive lung disease causing hypercapnia i.e. obesity hypoventilation and chest&#xD;
             wall disease, however these patients will be included if the FEV1/FVC ratio is &lt;60%&#xD;
             and the FEV1 &lt;50% if the predominant defect is considered to be obstructive by the&#xD;
             center clinician.&#xD;
&#xD;
          -  Clinical features of severe OSA&#xD;
&#xD;
          -  BMI &gt;35kg/m2&#xD;
&#xD;
          -  Unstable coronary artery syndrome&#xD;
&#xD;
          -  Cognitive impairment that would prevent informed consent into the trial&#xD;
&#xD;
          -  Psychiatric disease necessitating anti-psychotic medication, ongoing treatment for&#xD;
             drug or alcohol addiction, persons of no fixed abode post-discharge&#xD;
&#xD;
          -  Patients undergoing renal replacement therapy&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Inability to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Murphy, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Hart, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James' University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital / University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hopsital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guy's and St Thomas' NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Patrick Murphy</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Respiratory failure</keyword>
  <keyword>Non-invasive ventilation</keyword>
  <keyword>Home mechanical ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

